Innoviva, Inc.

Innoviva, Inc.

Innoviva, Inc.

Overview
Date Founded

1996

Headquarters

901 Gateway Boulevard,South San Francisco, CA 94080

Type of Company

Public

Employees (Worldwide)

5

Industries

Pharmaceuticals
Accounting & Financial Services
Biotechnology

Company Description

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR™ or BREO™ ELLIPTA™(FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. Our objective is to discover, develop and commercialize new medicines with superior efficacy, convenience, tolerability and/or safety.

Contact Data
Trying to get in touch with decision makers at Innoviva, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Chief Executive Officer

Chief Accounting Officer

Head, Exploratory Projects

Director, Strategic Marketing & Analytics

Vice President-Safety Assessment & Toxicology

Director

Director

Director

Board of Directors

Co-Founder at M.M. Dillon & Co. LLC

President at Haimovitz Consulting Group Ltd.

Director-Education & Training & Associate Professor at The Rockefeller University

Chief Medical & Scientific Advisor at ActivePure Technologies LLC

Senior Managing Director at Sarissa Capital Acquisition Corp.

Chief Legal Officer/General Counsel at Sarissa Capital Management LP

Paths to Innoviva, Inc.
Potential Connections via
Relationship Science
You
Innoviva, Inc.
Owners & Shareholders
Details Hidden

Sarissa Capital Management seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. Sarissa Capital Management conducts rigorous, fundamentals-based research. The funds’ portfolios will consist largely of exchange-traded securities (mostly equities but including equity-linked derivatives such as total return swaps and options), but the funds may also invest in a broad range of other financial instruments including, but not limited to, over-the-counter (OTC) equity securities and equity linked derivatives such as total return swaps and options (including index funds), privately placed securities of public issuers, preferred stock, currencies and fixed income securities (including credit default swaps).

Details Hidden

Atom Investors’s funds aims to provide attractive risk-adjusted returns over full-market cycles with less volatility than the broad equity markets. The firm seeks to achieve this investment objective through the use of a proprietary equity market-neutral investment strategy based upon fundamental research, quantitative analysis, the application of a systematic risk management program and systematic trading executions. They employ both long and short positions in a broad range of investment instruments which include securities, options, futures, currencies, derivatives and other instruments.

Details Hidden

Denali Advisors is a quantitative-based, institutional investment management firm which specializes in US value equities. Their approach focuses on identifying equity securities that possess high earnings coupled with lower relative liquidity. The firm uses non-biased, fundamental research in a scalable, systematic process based on their Network Value theory of investing. They seek out underappreciated, high earning stocks that have lower trading volume relative to their comparable which strives to build risk-controlled portfolios that outperform in various market environments. Denali Advisors offer institutional investors equity strategies covering value and core-oriented approaches in US Large, US Mid, US Small, US Micro, International Large-Cap and International Small.

Recent Transactions
Details Hidden

purchases Theravance Biopharma, Inc. from Innoviva, Inc.

Details Hidden

Innoviva, Inc. issued USD Common Stock

Details Hidden

Innoviva, Inc. issued USD Common Stock

Transaction Advisors
Underwriter

Advised onInnoviva, Inc. issued USD Common Stock

Underwriter

Advised onInnoviva, Inc. issued USD Common Stock

Underwriter

Advised onInnoviva, Inc. issued USD Common Stock

Legal Advisor

Advised onInnoviva, Inc. issued USD Common Stock

Managing Director

Advised onInnoviva, Inc. issued USD Common Stock

Founding Partner

Advised onInnoviva, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Advisor

Partner at Centerview Partners LLC

Consultant

Former Chief Executive Officer at Innoviva, Inc.

Clients

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Key Stats and Financials As of 2020
Market Capitalization
$1.16B
Total Enterprise Value
$1.61B
Earnings Per Share
$2.02
Revenue
$351M
Net Profit
$224M
TEVNet Income
7.19x
Debt TEV
0.24x
Total Debt
$386M
Total Equity
$608M
Enterprise Value / Sales
4.6x
EBITDAMargin
96.02%
Enterprise Value EBITDAOperating
4.79x
EBITDA
$337M
Three Year Compounded Annual Growth Rate Of Revenue
14.92%
Political Donations
$1,000
2002
Investments
Details Hidden

InCarda Therapeutics, Inc. develops transforming cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari and Carlos A. Schuler in 2009 and is headquartered in Brisbane, CA.

Investors
Details Hidden

Lauder Partners focuses on investments in various areas of the technology sector. The firm invests in companies as well as in funds, both venture and others. Lauder Partners invests the capital of Gary Lauder the Lauder family. Their areas of interest include cable TV technology, security, telecommunications and Internet technologies. Lauder Partners does not invest in content or cable programming. The firm considers investments in the US and Canada only and prefers them to be in close proximity to the Silicon Valley

Details Hidden

Head-Science & Development at Johnson & Johnson

Details Hidden

Co-Founder at Innoviva, Inc.

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust. It engages in the ownership, operation, development, and redevelopment of life science and technology properties. The firm also provides a space for lease to the life science and technology industries, which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Innoviva, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Innoviva, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Innoviva, Inc..